Price:
Rs. 5,875.00
Sample Type: PULMONARY
Fasting Not Required
Notes: A0115
Frequently Asked Questions (FAQ's):
What is the AFB XDR Screen by Hain LPA, Pulmonary Test?
This test uses the Hain Line Probe Assay to detect Mycobacterium tuberculosis DNA and mutations linked to resistance against first- and second-line anti-TB drugs in pulmonary samples.
Why is this test important?
It enables rapid identification of extensively drug-resistant TB, helping clinicians initiate appropriate therapy early and prevent further spread of resistant strains.
Who should undergo this test?
Patients with suspected pulmonary TB who have a history of treatment failure, relapse, or exposure to drug-resistant TB should undergo this test.
How is the test performed?
DNA is extracted from pulmonary samples (such as sputum) and analyzed using the Hain LPA at Metropolis Healthcare to identify drug-resistance mutations.
What do the results indicate?
Results indicate whether the Mycobacterium tuberculosis strain is resistant to first-line and second-line anti-TB drugs, guiding effective treatment strategies.
Are there any risks associated with the test?
The test is safe, with only minimal procedural risk associated with sample collection.
Why choose Metropolis Healthcare for this test?
Metropolis Healthcare provides rapid, accurate, and reliable XDR-TB detection using advanced Hain LPA technology and expert molecular interpretation for timely and precise patient management.